Articles tagged with Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have found that anti-cancer agents with low-molecular weights cannot reach tumors effectively due to obstructed small arteries. This limits the use of conventional chemotherapy and highlights the need for new treatments, according to Professor Tetsuya Kodama.
Researchers developed nanoparticles that can deliver immunostimulants via inhalation to induce systemic immune response against lung cancer. The treatment converted cold tumors to hot, immune-responsive tumors and showed significant regression of tumors in both lungs and prolonged survival of mice.
Researchers aim to reduce malnutrition among lung cancer patients by providing nutritional counseling and medically tailored meals. The study, funded by Bristol-Myers Squibb Foundation, will recruit up to 150 newly diagnosed patients with lung cancer across four medical centers.
A deep convolutional neural network-based software improved radiologist detection of malignant lung nodules by 70.3%, reducing false positives to 0.18 per X-ray. The study suggests machine learning methods can help overcome challenges in detecting lung lesions on chest X-rays.
Researchers at Stanford and UC-San Francisco have developed an experimental drug that targets lung cancer by neutralizing a single protein, slowing its growth. The decoy version of the receptor protein was engineered to preferentially bind to the protein, repelling other proteins involved in tumor growth.
The American College of Physicians (ACP) has released a new guidance statement for colorectal cancer screening in average-risk adults between 50 and 75 years old. The guidance suggests that physicians select the most suitable screening test for each patient based on factors such as benefits, harms, costs, availability, frequency, and p...
Researchers analyzed BTB and BBB changes in NSCLC brain metastasis over time, revealing key changes including loss of aquaporin-4 and zona occludens-1. These findings provide a comprehensive analysis of the transition of the blood-brain barrier to the blood-tumor barrier.
A high-fiber and yogurt-rich diet has been shown to reduce lung cancer risk by 33% compared to a low-fiber diet. The study's findings support the US Dietary Guidelines recommending a high fiber and yogurt diet for cardiovascular health and gastrointestinal cancer prevention.
A study of over 14,000 participants found associations between specific cigarette characteristics and lung cancer outcomes. Researchers analyzed data from a lung screening trial to investigate the impact of cigarette filter status, tar level, and menthol flavor on lung cancer outcomes.
Screening for ever-smokers with high lung cancer risk and long life-expectancy can prevent more deaths than current guidelines. A new study suggests using gains in life expectancy as a criterion to select candidates for screening, which could improve the balance of benefits and harms.
A new study presented at the IASLC 2019 North America Conference on Lung Cancer found that lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders. Low-dose computed tomography was shown to detect disease earlier in this population.
Researchers have discovered that patients' blood samples and tumour biopsies can reveal early signs of lung cancer spreading and becoming untreatable. The TRACERx project has identified possible causes of recurrence and developed new techniques to predict tumour aggression.
A study has identified key proteins in signaling pathways that control tumor growth in lung tissue, paving the way for personalized cancer treatment and new drug development. The research, published in Cell, also reveals new proteins activated by cancer mutations contributing to tumor growth.
A 40-year epidemiological study found that cancer incidence and mortality rates often move in concert for certain cancers, such as lung cancer, indicating a desirable trend. However, other cancers like thyroid, kidney, and melanoma show rising incidence rates with stagnant mortality rates, suggesting overdiagnosis may be at play
The breast cancer death rate has slowed in recent years, but the gap between black and white women remains significant. Breast cancer incidence rates have continued to rise, with a greater increase seen in hormone receptor-positive disease.
Researchers found that adding durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer in both chest and distant sites, with new lesions occurring primarily in the brain. This suggests that aggressive local therapies may further extend survival for patients with non-small cell lung cancer.
A phase II trial found that adding radiation therapy to immunotherapy increases progression-free survival for patients with metastatic non-small-cell lung cancer. T cells played a key role in the immune response, with certain markers predicting longer disease-free periods.
Researchers at Medical College of Georgia have found a link between high levels of TIMP-1 and IL-6, two molecules that contribute to chemotherapy resistance in non-small cell lung cancer. The study's findings suggest that elevated levels of these molecules may be an indicator of poor prognosis and a potential target for improving treat...
A study by VA Portland Health Care System and Oregon Health and Science University researchers found that early palliative care can increase survival in patients with advanced lung cancer. The study analyzed data on over 23,000 veterans and showed that palliative care provided shortly after diagnosis can lead to improved survival rates.
A new electronic nose can identify lung cancer patients who will respond to immunotherapy with 85% accuracy, outperforming the current gold standard of immunohistochemistry. The non-invasive test detects chemicals in patient breath and provides instant feedback, potentially avoiding ineffective treatment and side effects.
Scientists have identified distinctive characteristics of KRAS-positive lung cancers that can be targeted to inhibit growth, offering a new approach for personalized therapy. The study suggests exploring co-existing mutations as an alternative to traditional therapies.
Markey researchers identify nuclear glycogen's role in cancer progression and find epigenetic connections between glycogen metabolism and gene expression. The study reveals new therapeutic targets to treat non-small cell lung cancers.
Researchers developed a new classification method using artificial intelligence to identify primary cancerous tissue in head and neck cancers. The method achieved an accuracy of over 99% in distinguishing between primary lung squamous cell carcinomas and head and neck metastases, offering potential benefits for patients.
Patients taking nivolumab experience a significant five-fold increase in overall survival, with five-year rates of 13.4% compared to docetaxel's 2.6%. Long-term benefits and improved progression-free survival have been observed with nivolumab treatment.
A survey of European patients with lung cancer revealed that many were unaware of or had never heard of clinical trials. Despite positive experiences by over 50%, respondents identified difficulties in accessing trials, including language barriers, limited information, and disparities across Europe.
A nurse-led follow-up service has improved patient care for those with early-stage lung cancer by increasing clinic capacity, reducing waiting times, and ensuring continuity of care. The service also promotes junior medical training and is well-received by patients and the multidisciplinary team.
The Impower131 Trial found that atezolizumab + chemotherapy improved overall survival by 3.9 months compared to chemotherapy alone, particularly among patients with high PD-L1 expression. Treatment-related side effects were common but manageable in both arms.
The KEYNOTE-024 trial found that pembrolizumab significantly improved progression-free and overall survival in patients with advanced non-small-cell lung cancer. Patients treated with pembrolizumab had a median overall survival of 26.3 months compared to 14.2 months for those on chemotherapy.
The NLMT trial tests eight targeted therapies tailored to specific molecular changes in cancer cells. Researchers found promising responses with single-agent targeted therapy, particularly in oncogene-addicted NSCLC, and identified potential biomarkers for further research.
A Scottish study shows that combining an autoantibody test with CT imaging can significantly decrease late-stage lung cancer diagnoses and potentially lower lung cancer-specific mortality. The EarlyCDT-Lung Test identifies high-risk individuals, allowing for earlier interventions.
A new trial found that video-assisted thoracic surgery (VATS) significantly reduces in-hospital complications and shortens hospital stays compared to open surgery for early-stage lung cancer patients. VATS, a minimally invasive technique, showed improved outcomes without compromising oncologic results.
A European lung cancer screening model outperformed a US model in detecting cancers, with 99% of cancers found using the European method compared to 77%. The study found that the model detected more cancers among high-risk patients and had a higher accuracy rate.
The bioMILD trial demonstrated that a blood microRNA assay, combined with low-dose CT screening, is safe and effective in enhancing lung cancer prevention. Preliminary analysis showed a significantly higher lung cancer incidence and overall mortality in subjects with positive LDCT and/or miRNA at baseline.
A blood test has been shown to detect lung cancer earlier, identifying 32% of cases with a high specificity of 90%. This could lead to reduced late-stage presentations and improved survival rates for patients.
The MYSTIC trial found that patients with STK11 or KEAP1 mutations had poorer outcomes to anti-PD-L1 and anti-CTLA-4 immunotherapies compared to those without these mutations. ARID1A mutations were associated with improved survival in the durvalumab + tremelimumab arm.
Researchers studied the relationship between tumor mutational burden and response to immunotherapy with pembrolizumab. The study found that high or low TMB levels did not significantly impact overall survival, progression-free survival, or objective response rates for patients with metastatic nonsquamous non-small cell lung cancer.
The MYSTIC trial found that patients with STK11 or KEAP1 gene mutations in metastatic non-small cell lung cancer experienced poorer overall survival compared to those without these mutations. Additionally, patients with ARID1A mutations in the durvalumab + tremelimumab arm had longer median overall survival rates.
The bioMILD trial demonstrated that combining low-dose CT screening with a microRNA blood test reduces lung cancer mortality and incidence in high-risk individuals. The study found that participants with positive LDCT and/or miRNA at baseline had a significantly higher lung cancer incidence and overall mortality.
A Phase 1 study demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation. The therapy, AMG 510, showed encouraging anti-tumor activity with no dose-limiting toxicities or adverse events leading to discontinuation.
Research presented at the IASLC 2019 World Conference on Lung Cancer found that combining nivolumab with ipilimumab showed improved efficacy in patients with advanced non-small cell lung cancer (NSCLC), particularly those with high TMB or higher tumor PD-L1 expression. The safety profile of this combination therapy was also consistent ...
Researchers found no significant correlation between tumor mutational burden and response rates, progression-free survival, or overall survival in patients treated with pembrolizumab plus carboplatin and pemetrexed. High objective response rates were observed in both TMB low and high subgroups.
Cancer patients who continue smoking after diagnosis have a higher mortality rate and increased risk for second cancer development. The IASLC Declaration recommends screening all cancer patients for tobacco use and advising on tobacco cessation.
Researchers at H. Lee Moffitt Cancer Center describe a promising new treatment combination for patients with non-small cell lung cancer, showing preliminary efficacy and improved tolerance compared to standard treatments.
Researchers found a gene mutation in nearly half of dogs with lung cancer that could be treated with the same drug used for human breast cancer. A clinical trial is planned for dogs with naturally occurring lung cancer and the HER2 mutation.
Researchers at Moffitt Cancer Center have discovered a new treatment approach that may help nearly a third of lung cancer patients with KRAS mutations. The combination therapy targets the MEK kinase and enhances anti-tumor immunity through cytokines TNFα and IFNγ.
Researchers found that combining therapies reduced tumor relapse and side effects in mouse models of kinase mutated breast cancer. The study suggests using two therapies together, rather than one after the other, to improve treatment outcomes.
Researchers combine checkpoint blockade therapy with stem cell transplantation to boost efficacy in non-Hodgkin's lymphomas and melanoma. The approach increases cancer-killing immune response tenfold, allowing it to be effective for previously treatment-resistant cancers.
Researchers at Mayo Clinic have identified two distinct pathways for lung adenocarcinoma development, which can inform treatment strategies and predict patient response. The study's findings suggest that targeting specific pathways may provide alternative treatment options for patients with limited response to traditional therapies.
Scientists have developed a highly sensitive 'sniff-cam' that can detect low levels of disease biomarkers in breath, including diabetes, lung cancer, and Parkinson's disease. The device uses an ultraviolet ring light, filters, and a camera to measure volatile organic compounds (VOCs) in the breath.
Retinitis pigmentosa (RP) is caused by the starvation of photoreceptors due to disrupted glucose transport. Research led by UofL's Douglas C. Dean and Wei Wang found similar metabolic changes in lung cancer.
Researchers have discovered that two enzymes, SIK1 and SIK3, play a critical role in driving tumor growth in non-small-cell lung cancer by promoting inflammation. The findings highlight a potential new target for therapies and could lead to improved treatment options for patients with this deadly form of lung cancer.
A new AI tool developed by Dana-Farber Cancer Institute can extract high-value cancer outcomes from unstructured radiology reports with comparable accuracy to human reviewers. The tool, trained on over 14,000 imaging reports, was able to replicate human assessments of disease-free survival and progression-free survival.
A new study published in Science Advances reveals that a cellular switch called CREB plays a key role in directing tumor growth in non-small-cell lung cancer. Researchers found that blocking this switch could have therapeutic benefits for patients with this deadly type of cancer.
A new AI tool, CXR-risk, analyzes chest X-ray images to predict health and mortality, providing independent information that surpasses radiologists' readings. The study found that CXR-risk identified people at high risk for future heart attack, lung cancer, or death with accuracy.
A Northwestern University study found that many deadliest cancers, such as colon, lung, and liver cancer, receive significantly less nonprofit research funding than breast cancer, leukemia, and other well-funded types. This underfunding could impact research, drug development, and FDA approvals for these life-altering diseases.
Radiotherapy patients experiencing hurricane disasters had significantly worse overall survival rates than those completing treatment in normal circumstances. Longer disaster declarations were associated with increasingly worse survival outcomes.
Researchers at Massachusetts General Hospital have identified markers that can distinguish between major subtypes of lung cancer and accurately predict lung cancer stage. The study's findings could help physicians decide whether an individual patient with lung cancer benefits from standard treatment or needs more aggressive therapy.
Researchers found adding pembrolizumab to definitive treatment increased overall average PFS by 19.1 months, compared to 6.6 months in historical averages. The study showed the treatment did not lead to new safety issues or decreased patient quality of life.
Research reveals that epigenetic regulation-mediated metabolic reprogramming enables lung cancer cells to adapt to and resist targeted therapies. BCAT1 upregulation allows for glutathione generation, eliminating oxidative stress and promoting drug resistance.
A follow-up study reaffirms the effectiveness of low-dose computed tomography (LDCT) in reducing lung cancer mortality. The research found that LDCT can prevent lung cancer deaths or at least delay them for more than a decade, with only 303 patients needed to be screened to prevent one death.